Stay updated on Durvalumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Durvalumab Combo in Resectable NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision label on the header updated from v3.3.1 to v3.3.2.SummaryDifference0.1%

- Check12 days agoChange DetectedAdded Revision: v3.3.1 and removed Revision: v3.2.0 from the record history of NCT03794544. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedThe government funding operating status notice was removed from the page. The rest of the study history and related content remains unchanged.SummaryDifference0.5%

- Check33 days agoChange DetectedA new version entry (23) was added to the record history on 2022-02-23. It updates the Study Status and related documentation.SummaryDifference0.1%

- Check62 days agoChange DetectedUpdated operating status notice and version to v3.2.0; removes previous v3.1.0 reference and directs users to current status sources.SummaryDifference11%

- Check69 days agoChange DetectedUpdated the page from Revision: v3.0.2 to Revision: v3.1.0, signaling a new release version.SummaryDifference0.3%

Stay in the know with updates to Durvalumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Combo in Resectable NSCLC Clinical Trial page.